Quick Answer
NewAmsterdam Pharma Co N.V. reported Research And Development Expense of $141.83 million for the year ending 2025.
- NewAmsterdam Pharma Co N.V. showed a decrease of -6.3% in Research And Development Expense from 2024 to 2025.
- This data is from NewAmsterdam Pharma Co N.V.'s annual report (Form 10-K), filed with the SEC on February 18, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 6 years of available data (2020 to 2025), NewAmsterdam Pharma Co N.V.'s Research And Development Expense has grown by 3,406.4%.
- Historical annual values: Fiscal year 2025: $141.83 million | Fiscal year 2024: $151.41 million | Fiscal year 2023: $159.42 million | Fiscal year 2022: $86.74 million | Fiscal year 2021: $28.97 million | Fiscal year 2020: $4.05 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: